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autocrine prolactin loop enhancing inflammatory
response in monocytes
Gonzalo López-Rincón1,2, Ana L Pereira-Suárez3, Susana Del Toro-Arreola3, Pedro E Sánchez-Hernández3,
Alejandra Ochoa-Zarzosa4, José Francisco Muñoz-Valle5 and Ciro Estrada-Chávez1,6*Abstract
Background: Prolactin from pituitary gland helps maintain homeostasis but it is also released in immune cells
where its function is not completely understood. Pleiotropic functions of prolactin (PRL) might be mediated by
different isoforms of its receptor (PRLr).
Methods: The aim of this study was to investigate the relationship between the eventual synthesis of PRL and PRLr
isoforms with the inflammatory response in monocytes. We used THP-1 and monocytes isolated from healthy
subjects stimulated with lipopolysaccharide (LPS). Western blot, real time PCR and immunocytochemistry were
performed to identify both molecules. The bioactivity of the PRL was assessed using a bioassay and ELISA to detect
pro inflammatory cytokines.
Results: PRLr mRNA and PRL mRNA were synthesized in THP-1 monocytes activated with LPS with peaks of
300-fold and 130-fold, respectively. The long (100 kDa) and the intermediate (50 kDa) isoforms of PRLr and big PRL
(60 kDa) were time-dependent upregulated for monocytes stimulated with LPS. This expression was confirmed in
monocytes from healthy subjects. The PRLr intermediate isoform and the big PRL were found soluble in the culture
media and later in the nucleus in THP-1 monocytes stimulated with LPS. Big PRL released by monocytes showed
bioactivity in Nb2 Cells, and both PRL and PRLr, synthesized by monocytes were related with levels of nitrites and
proinflammatory citokines.
Conclusions: Our results suggest the expression of a full-autocrine loop of PRL enhances the inflammatory
response in activated monocytes. This response mediated by big PRL may contribute to the eradication of potential
pathogens during innate immune response in monocytes but may also contribute to inflammatory disorders.
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PRL is a hormone produced primarily by the anterior
pituitary gland and acts on different cell types [1]. PRLr
shares structures and signal transduction pathways with
the type 1 cytokines and their receptors. Type I long-
chain cytokines, such as IL-6, growth hormone and PRL* Correspondence: cestrada.ciatej@gmail.com
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PRLr lacks intrinsic kinase activity and the receptor-Jak2
acts in concert to transmit signals downstream of ligand
binding [3]. The main signaling networks downstream of
PRLr include the Jak-STAT [4], Ras-MAPK and PI3K-
AKT pathways [5]. Lymphoid cells express an autocrine
loop of PRL affecting proliferation, cytokine secretion and
immune activity [6-8]. However, studies with knockout
mice suggest that PRL-mediated signaling is not necessary
for immune response [9,10]. Nevertheless, little is known
regarding the expression of extrapituitary PRL and PRLr
isoforms in myeloid cells [11,12].entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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expression of PRLr in various lymphoid and non-lymphoid
organs [13]. Peritoneal macrophages (Mϕ) respond to PRL,
secreting IL-1β, TNF-α and IFN-γ through the activation of
the JAK2-STAT1 pathway [14]. In fibroblast treated with
proinflammatory cytokines, the expression of the long iso-
form of the PRLr (of 100 kDa) has been associated not only
with the phosphorylation of signal transducer and activator
of transcription 5B (STAT5B), but also with the inhibition
of the interferon regulatory factor 1 (IRF-1) and inducible
nitric oxide synthase (iNOS) expression [15]. In mono-
nuclear phagocytes, reprogramming is a regulatory process
useful during inflammatory response, driven by several
cytokines [16] and some hormones [17]. Although the role
of PRL during inflammation has been investigated in Mϕ
and fibroblast, the results might be considered controversial
due to masked effects of other molecules released by differ-
entiated inflammatory cells into the culture medium.
The PRL from pituitary gland may help to maintain
homeostasis during inflammatory responses throughout
the differential PRLr isoforms expression [12,15]. The
expressions of PRLr isoforms have been identified in
several tissues throughout the body [18], suggesting the
transcriptional and posttranslational regulation of PRLr
[19]. The expression of several isoforms also suggests
the activation of alternative signal transduction pathways
[20]. Likewise, the expression of an autocrine loop of
PRL in lymphocyte [6-8] implies that PRL and its re-
ceptor (PRLr) must be synthesized and that the ligand
is also secreted for the same cell; as well as, that this
released PRL has a bioactivity in the synthesizing cell
(e.g. proliferative responses). Although the expression
of PRL in peripheral blood mononuclear cells (PBMC)
has been noted [11,12], there is no complete evidence
of the expression of an autocrine loop with the partici-
pation of PRL in monocytes. Moreover, the precise role
and mechanism of action of PRL in mononuclear
phagocytes still remains elusive. We hypothesized that
the expression of an autocrine loop of PRL may play an
important role during the inflammatory response in
monocytes. Afterwards, the aim of this study became
investigating the relationship between the eventual
synthesis of PRL and PRLr isoforms with the inflam-
matory response elicited by LPS in monocytes.
To test this hypothesis, we used two kinds of human
monocytic cells activated with LPS in vitro: THP1 cell
line [17] and monocytes from healthy subjects, likely
with different genotypes. To avoid as many masked
effects in the culture media as possible, LPS doses and the
bacterial strain source were experimentally determined.
This was done to keep the great stimulation and the lower
differentiation of the cells towards macrophage phenotype.
The monocytic expression of PRLr and the local synthesis
of PRL were studied at both mRNA and protein levelsduring response elicited by LPS, using total protein
extracts, supernatants and nuclear protein extracts. The
PRL bioactivity (proliferation) was assessed in lactogen-
dependent Nb2 cells. We inmmunoinhibited the nitrates
and citokines release by monocytes after stimulation with
LPS for 48 h, using anti-PRL and anti-PRLr antibodies.
Methods
Reagents and antibodies
Human recombinant PRL (hrPRL) and LPS were obtained
from Sigma-Aldrich (St. Louis, MO). Some antibodies were
obtained from Santa Cruz Biotechnology (Santa Cruz, CA):
rabbit anti-PRLr (H-300) against residues from 323-622 in
the exon 10 sequence of the human PRLr, which recognize
long isoform (LF), intermediate isoform (IF), delta short
isoform 1 (ΔS1) and short isoform 1a (S1a); mouse
IgG1anti-PRL (E-9) against residues from 96 to 200 in the
exons 3, 4 and 5 of the human PRL; goat anti-mouse IgG-
HRP and goat anti-rabbit IgG-HRP. Mouse IgG1 anti-PRLr
(MAB1167) against human PRLr extracellular domain
(R&D Systems, MN) was previously used to neutralize
PRLr function [21]. A second mouse IgG1anti-PRL (6F11)
that recognized an epitope restricted to the carboxyl-
terminal disulfide loop conserved among prolactins from
several species was used (QED Bioscience, San Diego, CA).
The anti-human actin mAb was obtained from Chemicon
(Temecula, CA). Green-fluorescent Alexa Fluor® 488 goat
anti–mouse IgG isotype–specific, orange-Red fluorescent
Alexa Fluor® 568 goat anti–rabbit IgG isotype–specific, and
4'-6-Diamidino-2-phenylindole (DAPI) were obtained from
Gibco (Invitrogen Corp., Carlsbad, CA).
Experimental procedures with different cell lines and
isolated monocytes
THP-1 cells (ATCC®) were maintained in RPMI 1640
medium containing 10% (v/v) FBS and 1% (v/v) antibiotic-
antimycotic at 2 × 105 cell/ml as described [22]. THP-1 cells
in 6-well (Nunc) or 96-well plates (Corning) cultivated
for 0.5, 1, 2, 4 and 8 h were stimulated with LPS
(1 μg/ml). Nb2 cells were cultivated in high-glucose
D-MEM supplemented with 10% HS, 10% FBS and 10%
antibiotic-antimycotic as described [23]. MCF-7 breast
cancer cell line (ATCC®) was cultivated in RPMI 1640 as
reported [24]. Monocytes from PBMC were isolated
from heparinized (5 U/ml) blood of ten healthy male
donors (29.8 ± 7.4 years old) by a standard density gradi-
ent centrifugation at 400 g using lymphocyte separation
medium (Sigma Chemical) for 15 minutes at room
temperature as described [25]. The cells at the interface
were collected and washed three times in cold PBS
containing 0.1% BSA. PBMC were maintained 24 h in
RPMI 1640 medium containing 10% (v/v) FBS and 1% (v/v)
antibiotic-antimycotic at 5 × 106 cells/ml. Non-adherent
cells were removed by washing in BSA-PBS and then
López-Rincón et al. Journal of Inflammation 2013, 10:24 Page 3 of 12
http://www.journal-inflammation.com/content/10/1/24remaining adherent cells (>95% CD14+ cells) were culti-
vated and stimulated 8 h with LPS (1 μg/ml). Healthy
donors volunteered to participate and signed the in-
formed consent letter before inclusion in the study. The
investigation was performed according to the ethical
guidelines of the 2008 Declaration of Helsinki and was
approved by the ethical investigation and biosecurity
committee of the University Center of Health Sciences
at the University of Guadalajara. To determine the dose
and source of LPS used in this study we performed
dose-response assays using LPS from Salmonella enterica
serotype Minnesota and Escherichia coli 0111:B4. After
that, we choose the highest dose of S. enterica LPS for
priming cells, avoiding as much as possible the differenti-
ation of monocytes towards Mϕ phenotype.
Nb2 cell bioassay of THP-1-treated supernatants
Supernatants were obtained by incubating non-confluent
THP-1 (7 × 105 cells/ml) for 1, 2, 4 and 8 h with LPS
(1 μg/ml). The supernatants were concentrated 24-
fold using Centricon 10 (Millipore, Billerica, MA).
Nb2 cells (4 × 104 cells/ml) were cultured for 60 h with
serial dilutions of treated or control concentrated superna-
tants (5, 10, 20 and 45 μL). Nb2 cell proliferation and viabil-
ity were measured with reduction of MTT as described
[26]. Bioactivity was extrapolated from a standard dose-
response curve with recombinant hPRL (1, 10, 100, 500
and 1,000 pg/ml). Bioactivity was inhibited with 4 μg of
α-human PRL (E-9) for each dilution assayed.
Real-time RT-PCR
Total RNA was extracted from THP-1-MO (Trizol,
Invitrogen) and cDNA was synthesized (Superscript III,
Invitrogen). PRLr and PRL transcripts were measured in
triplicate by real-time quantitative RT-PCR using Applied
Biosystem PRISM 7300 (Applied Biosystems, Foster City,
CA). To amplify the conserved region of PRLrmRNA, the
following forward and reverse primers were used: 5′-AGA
CCA TGG ATA CTG GAG TA -3′and 5′-GGA AAG
ATG CAG GTC ACC AT -3′, respectively (Primer Express;
Applied Biosystems). The fluorogenic probe used for
PRLr was 6FAM - TCT GCT GTC ATC TGT TTG
ATT A (Applied Biosystems). To detect the PRL mRNA,
exons 4-5 were amplified with the primers and the
probe 6FAM corresponding to assay IDHs01062137_m1
(Applied Biosystems). The 18S ribosomal RNA (rRNA)
gene (Applied Biosystems) was used as a housekeeping
gene and comparative Ct (2
-ΔΔCt) method for relative
expression was analyzed as described [27].
Western blot (WB) protocol and analysis
THP-1 cells or monocytes from donors were harvested,
washed twice with phosphate-buffered saline (0.01 M
phosphate buffered saline (NaCl 0.138 M; KCl - 0.0027 M);pH 7.4, at 25°C), and disrupted with RIPA buffer
(Sigma-Aldrich, St. Louis, MO) containing 150 mM NaCl,
1.0% IGEPAL® CA-630, 0.5% sodium deoxycholate, 0.1%
SDS, 50 mM Tris, pH 8.0. Next, protease (1 μM pepstatin
A, 2 μM leupeptin, 0.3 μM aprotinin, 2 μM chymostatin,
2 μM antipain and 0.1 mM PMSF) and phosphatase in-
hibitors (0.2 mM Na3VO4 and 5 mM NaF) were added
and finally clarified by centrifugation at 4°C for 20 min.
Protein concentration was determined by Lowry method
(BCA Protein Assay Reagent, Pierce). Total proteins 40 μg
were electrophoretically separated by 10% SDS-PAGE and
transferred to PVDF membrane (Bio-Rad) and blocked
with 5% (wt/v) skimmed milk and 1% (wt/v) BSA. After-
wards, membranes were incubated with anti-PRLr(H-300)
or anti-PRL (E-9) antibodies diluted 1:200 at 4°C overnight.
HRP-conjugated anti-rabbit or anti-mouse secondary anti-
bodies and a chemiluminescence system were used for blot
development (Pierce). Intensity of bands was quantified by
densitometry using Gel Logic 112 imaging system and
molecular imaging software, 5.0 (Kodak, Rochester, NY).
β-actin levels were determined as an internal control.
WB figures are representative of three independent ex-
periments with similar results.
Nuclear protein extraction
THP1 cells stimulated with LPS were harvested after
48 h for the nuclear protein extraction with a kit
(CelLyticTMNuCLEARTM Extraction, Sigma-Aldrich).
According to the manufacturer’s instructions, cells were
allowed to swell with hypotonic buffer. Once disrupted,
the cytoplasmic fraction was removed and the nuclear
proteins were released from the nuclei precipitated with a
high salt buffer.
Fluorescent immunocytochemistry
THP-1-MO (7.5 × 103 cells/100 μL) were harvested by
cytospin (Stat Spin Express 2 centrifuge, Norwood, MA),
plated on Kling-on HIER slides (Biocare Medical,
Concord, CA), fixed in 4% (v/v) formaldehyde at −20°C
for 10 min and blocked with PBS supplemented with 10%
(v/v) FBS and 1% (w/v) BSA at room temperature for 1 h.
Next, cell preparations were washed and incubated with
1:50 anti-PRLr or 1:500 anti-PRL at 4°C overnight; and
then incubated with 1:1,000 Alexa Fluor® 488-conjugated
α-mouse or Alexa Fluor® 568-conjugated anti-rabbit
for 1 h. Cell nuclei were counterstained with 1 μg/ml
DAPI. Nonspecific immunolabelling was determined
omitting primary antibodies. All experiments were
performed in triplicate. Fluorescence microscopy was
performed with an AxioImager 2 fluorescence micro-
scope (Carl Zeiss, Göttingen, Germany). Images were
captured using an AxioCamMRm camera (Carl Zeiss)
and the AxioVs40 V 4.8.2.0 software (Carl Zeiss). Signal in-
tensity was quantified using densitometry with the Imagen
López-Rincón et al. Journal of Inflammation 2013, 10:24 Page 4 of 12
http://www.journal-inflammation.com/content/10/1/24J 1.43 μ software from the National Institutes of Health.
Images from 30 cells positive for PRL and PRLr labeling
were collected and quantified; integrated density was the
sum of the pixel values.
Nitric oxide determination
The oxidation products of nitric oxide in THP1 and
fresh monocytes were determined in cell culture media by
the Greiss (G4410, Sigma-Aldrich) reactions as previously
described [28]. Nitrite content was quantified by extrapola-
tion from sodium nitrate standard curve in each experi-
ment (14.4, 11.2, 8.4, 5.6, 2.8, 1.4, 0.7 μM). Normalized
results after subtracting the value obtained with untreated
cell cultures were considered for comparisons. The concen-
tration of nitrite was inmunoinhibited with 4 μg of mAb
anti-PRL (E-9) in monocytes cultures.
Cytokine assays
THP1 cells were stimulated with LPS and supernatants
were harvested and stored at -80°C after 48 h until analysis.
Using ELISA with pre-coated plates (LEGEND MAX™,
BioLegend Inc., San Diego, CA) the levels of human
IL-1β (435007), human IL-6 (430507) and human TNF-α
(430207) were measured according to the manufacturer’s
instructions. The immunoinhibition of citokines release
was performed with 10 μg of mAb anti-PRLr (MAB1167)
in monocytes cultures.
Statistical analysis
The mean values ± SD from a representative experiment
are shown for samples measured in triplicate. Statistical
analysis was performed with a two-way ANOVA comparing
treated versus untreated control and measurement periods
as the independent variables. The Bonferroni test was used
to adjust for multiple comparisons. Data were analyzedFigure 1 PRLr mRNA and PRL mRNA synthesis in THP-1 monocytes ac
with LPS 1 μg/ml were harvested at different times and three independent
method for: A, PRLr mRNA; and B, PRL mRNA. Data are expressed as mean
p<0.05*, p<0.01**, p<0.001***; and between 2 versus 4 h p<0.01††.using GraphPad Prism version 5.03 (San Diego California,
USA). Significance was defined as p<0.05.
Results
To choose the dose of LPS to stimulate our culture
cells, avoiding the differentiation of monocytes towards
Mϕ phenotype as much as possible, we performed
dose-response assays using LPS from Salmonella
enterica serotype Minnesota and Escherichia coli 0111:
B4 (Additional file 1: Figure S1). Nitrates released indicated
that THP-1 monocytes stimulated with 1 μg of LPS of
S. enterica showed significant difference in comparison
with not only lower but also higher doses (p<0.05)
(Additional file 1: Figure S1A) after 48 h. Similar results
were found using same doses of LPS of E. coli (p<0.01)
(Additional file 1: Figure S1B). Cytometry analyses of
THP-1 cells stimulated showed significant differences in size
versus granularity when LPS of E. coli was used in compari-
son with LPS of S. entrerica (Additional file 1: Figure S1E).
Whereas E. coli LPS induced and increased the cell size, S.
entrerica did not. In addition, the cells maintained similar
granularity compared with the untreated cells after 48 h
(Additional file 1: Figure S1C). Kinetic of nitrates released
showed only significant differences when LPS of S. enterica
was used for 48 h, but not with E. coli (Additional file 1:
Figure S1D) nor before 48 h of stimulation with either. Tak-
ing these results into account, to induce an inflammatory
response we used 1 μg of LPS of S. enterica, maintaining
undifferentiated monocytic cells. These included both the
THP-1 cell line and those obtained from peripheral mono-
nuclear blood cells of different healthy donors.
PRLr mRNA and PRL mRNA were synthesized in THP-1
monocytes stimulated with LPS
PRLr mRNA and PRL mRNA RT-PCR assays were
performed to determine if THP-1 monocytes treated withtivated with LPS using real-time PCR. THP-1 monocytes stimulated
RT-PCR experiments were analyzed using comparative Ct (2-ΔΔCt)
± SD, and significance versus untreated (UT) control is defined as
Figure 2 PRLr and PRL expression in THP-1 monocytes activated with LPS using Western blot. THP-1 monocytes stimulated with LPS
1 μg/ml were harvested at different times and two independent Western blot experiments were performed and analyzed using densitometry
analysis (graph): A, PRLr; and B, PRL. As positive controls of PRLr isoforms the total protein extract from breast cancer cell line (MCF-7), showing
short, intermediate and long isoforms, was included. A positive control for human recombinant PRL (hrPRL) showing 50, 23 and 16 kDa forms
was included. Anendogenous control of β-Actin showing 43 kDa was revealed. Data are expressed as mean ± SD, and significance vs. untreated
(UT) control is defined as: p<0.05*; p<0.01**; and between 1 versus later hours p<0.05†; p<0.01††.
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expression of total PRLr mRNA increased over 300-fold
from 1 h to 72 h (p<0.001) after LPS treatment, except at
4 and 8 hours when increases were 223-fold (p<0.05) and
247-fold (p<0.01), respectively (Figure 1A). The difference
in the PRLr mRNA synthesized between 2 and 4 h wasFigure 3 PRLr and PRL expression in monocytes isolated from periph
isolated from PBMC of different healthy male subjects were tested by West
B, PRL. Total extract proteins of the breast cancer cells (MCF-7) or human r
expression was revealed as endogenous control and graphs show densitom
expressed as mean ± SD, and significance is defined as p<0.05*, p<0.01**;significant (p<0.01) as well. The expression of PRL mRNA
increased 80-fold (p<0.05) and 133-fold (p<0.01) after 1
and 2 h of LPS stimulation, respectively. Then, PRL
mRNA decreased below 30-fold (p<0.01) at 4 h, increased
80-fold (p<0.05) at 8 h, and again decreased below 30-fold
after 48 h (p< 0.05) (Figure 1B).eral mononuclear cells (PBMC) of healthy donors. Monocytes
ern blot analysis after activation with LPS 1 μg/ml for 8 h: A, PRLr; and
ecombinant PRL (hrPRL) were used as positive controls. β-Actin
etry analyses. Experiments were performed in triplicate. Data are
p<0.001*** versus control.
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stimulated with LPS
Two PRLr isoforms of 100 and 50 kDa were identified in
THP-1 monocytes by Western blot until 8 h of stimulation
with LPS (Figure 2A). In relation to untreated cells, the
expression of the 100 kDa isoform increased from 1 to 8 h,
except at 4 h when the expression was significantly lower in
comparison with any time after stimulation with LPS
(p<0.01) (Figure 2A). A basal expression of the PRLr iso-
form of 50 kDa was observed (Figure 2A), but an increase
in a time-dependent manner was found from 4 h (p<0.05)
to 72 h (p<0.01) after LPS stimulation (Figure 2A). Also, a
continuous increased expression of PRL of 60 kDa in THP-
1 monocytes was detected from 1 to 8 h after stimulation
with LPS; then, after 48 h the expression of a bigger PRL of
80 kDa was detected (Figure 2B). No basal expression of
PRL was detected in untreated cells (Figure 2B).
Isoforms of PRLr and PRL were expressed by monocytes
from healthy subjects after stimulation with LPS
In untreated monocytes obtained from healthy subjects a
PRLr isoform of 50 kDa (Figure 3A) and PRL of 60 kDaFigure 4 Colocalization of PRLr and PRL in THP-1 monocytes activate
and PRL was performed with THP-1 monocytes activated with LPS 1μg/ml
i. Representative results for PRLr, a, d and g; PRL, b, e and h; as well as, mer
(1250X). The nucleus was counterstained with DAPI and an overlay was pe
PRL (white) was quantified using densitometry and compared between 1,
triplicate, and significance is defined as p<0.001**; p<0.0001*** vs. control o
and D, PRL with culture supernatant and nuclear extracts after stimulation
hrPRL were used; and β-Actin was revealed as an endogenous control.and 23 kDa were found (Figure 3B). Until 8 h after
stimulation with LPS, the increased expression of PRLr
isoforms of 50 kDa (p<0.05) and 100 kDa (p<0.001)
(Figure 3A) and PRL of 60 kDa (p<0.01) was observed, as
well as, the decrease of PRL of 23 kDa (p<0.01) (Figure 3B).
After 48 hours of stimulation with LPS the increased
expression of PRLr isoforms of 100, 90, 65 and 50 kDa
(Figure 3A), and the increase of the 80 kD PRL (p<0.001)
was revealed, as well as a decrease of PRL of 60 kDa
(Figure 3B). PRL of 23 kDa was not detected after 8 h of
stimulation with LPS (Figure 3B). Using a second Mab
against human PRL (6F11), the expression of a PRL-like
protein of 80 kDa in samples of THP-1 monocytes, as well
as, monocytes derived from peripheral blood mononuclear
cells of healthy donors was confirmed, using both total or
nuclear protein extracts (Additional file 2: Figure S3).
PRLr and PRL were colocalized inTHP-1 monocytes
stimulated with LPS
To determine the localization of PRLr and PRL, fluorescent
immunocytochemistry assays were performed with
THP-1 monocytes treated with LPS. A staining patternd with LPS. A, fluorescent immunocytochemistry (FI) to detect PRLr
and harvested after: 1 h, a, b and c; 4 h, d, e and f; 8 h, g, h and
ged by double immunocytochemistry for PRLr and PRL are shown
rformed. B, cell signal intensity obtained with FI for PRLr (black) and
4 and 48 h after stimulation with LPS. Experiments were performed in
r between 1 and 4 h p<0.0001†††. C, Western blot analysis of PRLr;
with LPS are shown. As positive controls, total MCF-7 extracts and
Figure 5 Bioactivity of PRL of culture supernatants of THP-1
monocytes activated with LPS. A, Western blot analysis of PRL
with supernatants of THP-1 monocytes activated with LPS 1 μg/ml
and harvested at different times after treatment. B, proliferation
bioactivity in concentrated supernatants (24X) was assayed in Nb2 cell
cultures after addition of different volumes: 5, 10, 20 and 45 μl; and C,
including anti-PRL mAb E-9 (dashed line) for inmunoinhibition.
Proliferation expressed as OD550nm (left Y axis) or extrapolated and
expressed in picograms (right Y axis) are shown. All experiments were
performed in triplicate and data are expressed as mean ± SD (n = 3).
Significance is defined as p<0.05*, p<0.001**, p<0.0001*** versus control.
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of cells from 1 to 8 h (Figures 4Aa, Ad and Ag); a scanty
label of PRLr was also observed in culture media (fixed
surrounding cells) within 2 h after stimulation with LPS
(Figure 4Aa). Likewise after 1 h, PRL expression in THP-1
monocytes (in green) was observed in the media and on
the cell surface (Figure 4Ab). The PRL expression was
observed once again after 8 h in cytoplasm (Figure 4Ae)
and later in the nucleoplasm (Figure 4Ah). Using double
immunolabelling colocalization of PRL and PRLr was
observed in the cellular surface (in orange) (Figure 4Ac)
and cytoplasm (in magenta) of THP-1 monocytes from 1 to
8 h (Figure 4Af) after stimulation with LPS; and then in the
nucleoplasm (yellow) after 48 h (Figure 4Ai). Densitometry
supported a significantly induced expression of PRLr
(p<0.001) and PRL in stimulated monocytes (p<0.001) after
8 h in comparison with untreated cells (Figure 4B). To as-
sess the release of soluble molecules of PRLr and PRL and
its likely translocation to the nucleus, cell-free supernatants
from culture media and nuclear protein extracts of THP-1
monocytes treated with LPS were analyzed. The results re-
vealed soluble isoforms of both PRLr of 50 kDa (Figure 4C)
and PRL of 60 kDa (Figure 4D) that decreased from 1 to
48 h. They also showed the translocation of PRLr isoform
of 60 kDa and PRL of 80 kDa to the nucleus that increased
between 1 and 48 h. In contrast neither PRLr (Figure 4C)
nor PRL (Figure 4D) were found in supernatant and nuclear
extract proteins of untreated cells. When primary antibodies
against epitopes in the PRL and PRLr sequences were
omitted, no signals were revealed by fluorescent immuno-
cytochemistry assays using same conditions with mono-
cytes and LPS stimulation (Additional file 3: Figure S2).
PRL of 60 kDa released from LPS-stimulated THP-1
monocytes showed bioactivity in Nb2 Cells
To determine the proliferative bioactivity of PRL synthe-
sized and released by THP-1 monocytes after stimulation
with LPS, the culture supernatants were harvested from 1
to 8 h and tested in a proliferation assay with lactogen-
dependent Nb2 cells. Western blot analyses of supernatants
showed only PRL of 60 kDa (Figure 5A). Results of bioassay
showed that bioactivity in culture supernatants decreased
in a time-dependent manner from 1 to 8 h (Figure 5B); and
differences between early supernatants of 1 h compared
with later results of 2, 4 and 8 h were significant (p<0.001)
with every volume assayed; and with 20 μl equivalents to
2 ng/ml (p<0.001) (Figure 5B). Using a volume of 20 μl
and supernatants of 2, 4 and 8 h, the highest values of
bioactivity were observed, equivalent to 900 pg/ml of hrPRL
(Figure 5B); and using higher volumes of 45 μl, lower
values were observed (500 pg/ml; p<0.01). Significant
immunoinhibition of PRL bioactivity was demonstrated
after the addition of mAb anti-PRL (E-9) to each of the
supernatants assayed (p<0.001) (Figure 5C).PRL and PRLr synthesized by monocytes were related
with nitrites and proinflammatory cytokines
Basal levels of nitrates were found in the culture super-
natants of stimulated monocytes with LPS. They were
harvested at 8 h (10 μMoles) for both THP-1 and fresh
isolates from healthy subjects (Figure 6). After 48 h of
stimulation with LPS nitrite, the concentration increased
3 times in THP-1 (over 30 μMoles) (p<0.001) and 2
times in fresh monocytes (p<0.01). The concentration of
nitrite was inmunoinhibited in the presence of mAb–PRL
(E-9) for THP-1 monocytes (p<0.001) and fresh monocytes
(p<0.01) (Figure 6). In THP-1 monocytes, an increase in
the release of cytokines IL-1β (>600 pg/ml) (p<0.001), IL-6
(600 pg/ml) (p<0.001) and TNF-α (<25 pg/ml) (p<0.001)














































Figure 6 Inhibition of nitrite response of monocytes activated with LPS using a mAb anti-PRL. NO3 and NO2 were assayed in culture
supernatants of monocytes at 8 and 48 h after stimulation with of LPS 1 μg/ml and, as well as with mAb anti-PRL (E-9): A, THP-1; and B, fresh
monocytes from different subjects. Experiments were performed in triplicate. Data are expressed as mean ± SD, and significance versus UT control is
considered as p<0.001***; p<0.01**; or between cell cultures treated with LPS alone versus LPS and mAb anti-PRL together, as p<0.01††; p<0.001†††.
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was detected (Figure 7). The immunoinhibition with a pAb
anti-PRLr (MAB1167) completely struck the levels of IL-1β
(p<0.001) and IL-6 (p<0.001), reducing the TNF-α concen-
tration of 0.6 times (~15 pg/ml) (p<0.05), and inducing
release of IL-10 (~ 0.5 pg/ml) (p<0.05) (Figure 7).
Discussion
Ubiquitous expression of PRLr and PRL mRNA in T lym-
phocytes has suggested possible autocrine or paracrine PRL
immune effects [6]. However, results obtained with the
knockout approach pointed out an insignificant role of the
PRLr and PRL in the immune response maintenance [9,10].
Therefore, these molecules might be involved in the biology
of other immune cells distinct from lymphoid, e.g. myeloid
cells [29]. Indeed, some reports indicate that PRL from the
pituitary gland induces production of nitric oxide and
TNF-α in murine peritoneal Mϕ, a process involving pro-
tein tyrosine kinases, MAP kinases and Ca++ channeling
[30]. On the other hand, the inhibition of inducibleFigure 7 Inhibition of proinflammatory cytokine response of THP-1 m
TNF-a and IL-10 were assayed in culture supernatants of THP-1 monocytes
48 h. Differences among untreated cells vs. LPS treated are considered sign
LPS alone versus LPS and pAb anti-PRLr as p<0.05†; p<0.001†††.nitric oxide synthase expression by pituitary PRL has
previously correlated with JAK-STAT-5b activation
and the suppression of IRF-1 in lung fibroblasts [15].
Using an acute inflammation model induced with LPS
in mice and characterized by proinflammatory cyto-
kine synthesis, it has been shown that PRLr mRNA is
differentially expressed [13]. Nevertheless, the same
cytokines induce the expression of PRLr isoforms that
may allow PRL to inhibit the nitrosative stress in pul-
monary fibroblasts [15].
Therefore, we hypothesized that the expression of an
autocrine loop of PRL might play an important role dur-
ing the inflammatory response in monocytes. To study
the inflammatory response with LPS, the human mono-
cytic leukemia-derived THP-1 cell differentiated with
phorbolmyristate has been useful [22,31]. LPS is instant-
aneously recognized by TLR4 expressed by monocytes
[22,31,32]. TLR4 is associated with MD-2 on the cell
surface and this is required for induction of inflamma-
tory cytokines. Additionally, LPS-binding protein (LBP)onocytes activated with LPS using a pAb anti-PRLr. IL-1β, IL-6,
activated with LPS alone or including pAb anti-PRLr (MAB1167) after
ificant as p<0.05*; p<0.001***; or between cell cultures treated with
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binds LBP and delivers LPS-LBP to the TLR4-MD-2
complex. TLR4 is known to activate two signaling path-
ways: the myeloid differentiation primary response gene
88-dependent pathways and the TIR-containing adapter
inducing IFNβ-dependent pathway. Signaling pathways
via TLR4 mediated by these adapter molecules conclude
in the activation of NF-kB, and/or mitogen-activated
protein kinases, and/or the transcription factor IFN
regulatory factor 3. Activation of these molecules regu-
lates the expression of diverse inflammatory genes as
type I IFN [33]. LPS is a specific ligand for TLR4, but
cytokines and hormones may cooperate to enhance
eradication of pathogens from the circulation system
and tissue sites [34]. In this work, in order to avoid
masked effects of other molecules released by differenti-
ated Mϕ into the culture medium, we used undifferenti-
ated monocytes including the cell culture line THP-1
and fresh monocytes isolated from subjects likely with
different genotypes.
We used primers to amplify the conserved region of
PRLr mRNA from all isoforms that retain 175 bp of
the exons 7, 8 and 9 (GenBank ID: NM_001204315.1),
including: LF, intermediate isoform (IF), and short
isoforms, ΔSF1, SF1a, SF1b, Δ4-SF1b, Δ4/6-SF1a, SF1c;
and to detect the PRL mRNA, exons 4-5 were ampli-
fied. For inmunoassays to detect the PRL and PRLr
proteins, we used the mAb E-9 against an epitope in
the PRL sequences, as well as the polyclonal antibody
(pAb) H-300 against an epitope in PRLr sequence. The
pAb H-300 was recently deemed specific and useful to
perform immunehystochemical assays in human tissue
samples [35]. In the case of anti-PRL, we chose the
mAb E-9 against a conserved sequence of PRL, previously
characterized by others [36-40].
The synthesis and expression of PRLr isoforms of 50 and
100 kDA and the isoform PRL of 60 kDA were demon-
strated in THP-1 monocytes activated with LPS in this
work, using transcriptional and translational approaches as
previously described by others [6,27,35]. The LF of 100 kDa
was inversely related with the IF of 50 kDa that was
expressed at basal levels. This differential expression
suggests a transcriptional regulation of the LF and IF as
described in breast carcinoma cells [41]. However, these
isoforms might be also posttranslationally regulated [42]
and proteolysis of the LF can produce shorter isoforms
[43]. The IF has been proposed to mediate diverse PRL
functions in other cells [44]. In addition to the structural
diversity of PRLr, different concentration-dependent
functions may exist.
Our results were also supported using monocytes from
healthy subjects. Other isoforms of PRLr of 90 and 65
kDa and PRL of 23 kDa were also detected after stimulation
with LPS. Long (90 kDa) and short (42 kDa) PRLr isoformsresulting from differential splicing [45] and an intermediate
isoform (65 kDa) from an in-frame truncation have been
previously reported in other cell lineages, including human
mammary tumor [46]. Previous findings suggest that PRL
from the pituitary gland might help to maintain homeosta-
sis during inflammatory responses through the differential
expression of PRLr isoforms [12,15,47]. The dominant nega-
tive character of short PRLr isoforms (40 kDa) has been de-
scribed in human cells [19], whereas the LF (100 kDa) and
the IF (50 kDa) might trigger different signaling pathways
[42]. Indeed, human prolactin receptor (PRLr) transcripts
and their protein products exhibit heterogenic structures
and functions [42], and at least ten isoforms of human PRLr
have been identified [18,48]. Short form homodimers and
long and short form heterodimers were found constitu-
tively present in humans. These mediate the activation
of JAK2, but are unable to signal through JAK2/STAT5
[20]. In addition to modulating signaling by PRLr
heterodimerization, short forms might activate distinct
signaling pathways [49].
The molecular heterogeneity of PRL has been described
[50] and in this work we demonstrated that the monocytes
activated increased synthesis and expression of a big PRL
of 60 kDa. This big PRL has been previously characterized
in serum, plasma, PBMC and lymphocytes from human
subjects [6,51,52]. The big PRL is a dimer of covalently-
linked glycosylated subunits (25 kDa) [51] with reduced
biological activity [53] and might be involved in mecha-
nisms of secretion, storage [54] and proteolysis [51]. In
this work, a high proliferative bioactivity of the PRL of 60
kDa was demonstrated using lower volumes in a bioassay,
suggesting the saturation of receptors available in the
bioassay system. These results agree with what is known
about Nb2 cells in which PRLr is abundant and only par-
tial occupancy on the surface is required to reach maximal
proliferative bioactivity [55].
In addition, we demonstrate that PRL and PRLr syn-
thesized by monocytes activated with LPS were related
with the production of nitric oxide and proinflammatory
citokines (IL-1β, IL-6 and TNF-α), since the secretion of
these molecules was inhibited using primary antibodies
that recognized both PRL and PRLr. The PRL of 23 kDa
was not found in monocytes activated with LPS after 8 h,
but it was revealed in fresh untreated monocytes from
different subjects. Therefore, this 23 kDa PRL was likely
released from pituitary gland and transient bound to the
PRLr in the monocyte. In a previous report, the activation
of monocytes with both LPS and high concentrations
of PRL mimics physiological hyperprolactinemic states,
such as during pregnancy, promoting proinflammatory
responses via NF-kB and IRF-1, as well as IL-10 release
[56]. In this work, IL-10 was neither released by untreated
nor LPS-activated monocytes, but, in contrast, the binding
of PRLr with a pAb anti-PRLr elicited IL-10 in activated
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activated monocytes/macrophages seems to be regulated by
a direct downstream effector kinase (serine/threonine) of
PI3K [57-60]. The PI3K-AKT signaling pathway plays a role
in regulating cellular growth, differentiation, adhesion,
and inflammatory responses. Taking the background into
account, AKT activation elicited by bound PRLr (65 kDa)
was probably responsible for IL-10 production and subse-
quent IL1-β, IL-6, TNF-α and nitric oxide drop. Recently,
the activation of the human PRL extrapituitary promoter
in monocytes activated with LPS was noticed as being
greatly regulated and involved with the resolutive phase of
inflammation [61]. However, the big PRL has been
formerly correlated with the course of several inflamma-
tory disorders [29,62]. Our results suggest that monocytes
might contribute as a source of PRL found in sera patients
that have chronic systemic inflammation.
Molecular colocalization performed by fluorescent
immunocytochemistry assays suggests the interaction of
PRLr with big PRL synthetized by monocytes after activa-
tion with LPS. The interaction might not only take place
in the surface of the cells, but also at an early point in the
milieu and later in the cytoplasm of activated monocytes.
In addition, we demonstrate a time-dependent nuclear
translocation of the PRL that had a molecular weight of
80 kDa instead of 60 kDA, as well as a PRLr isoform of 50
kDa. It is possible that the PRL of 80 kDa corresponds to
a protein complex of big PRL of 60 kDA covalently linked
with a PRL-interacting protein [6,51-53]. Therefore as
previously proposed in cancer cells [63,64], ligand-induced
complex imported to the nuclei might mediate some
genetic effects of PRL in activated monocytes.
Conclusions
Our results suggest that the expression of a full-autocrine
loop of PRL enhances the inflammatory response in acti-
vated monocytes. This response mediated by big PRL might
contribute to the eradication of potential pathogens during
innate immune response in monocytes. In addition,
this autocrine loop might prevent the resolution of sys-
temic inflammation during inflammatory disorders in
humans. Further analyses are needed to characterize
the molecular mechanism regulating this autocrine
PRL loop in monocytes.
Additional files
Additional file 1: Figure S1. Nitrite response assays using different
doses of LPS to activate THP-1 monocytes. NO3 and NO2 were assayed in
supernatants of THP-1 monocytes stimulated with different doses of LPS
after 48 h. A, results with LPS of Salmonella enterica serotype Minnesota;
and B, of Escherichia coli 0111: B4 strain. C, flow cytometry forward (FSC)
and side scatters (SSC) of THP-1 monocytes untreated (UT), stimulated
with LPS of S. enterica (1 μg/ml) and LPS of E. coli (1 μg/ml). NO3 and NO2
were assayed in supernatants of THP-1 monocytes stimulated with LPS1 μg/ml and harvested at different times with: D, LPS of S. enterica and E,
LPS of E. coli. Experiments were performed in triplicate, data expressed are as
mean ± SD and significance is defined versus UT control as p<0.05*; p<0.01**.
Additional file 2: Figure S3. Expression of big PRL of 80 kDa in
peripheral blood mononuclear cell-derived monocytes (MO-PBMC) and
THP-1 monocytes (MO-THP1). Monocytes were stimulated with LPS of
Salmonella enterica serotype Minnesota and after 48 h, A) total protein
extracts, or B) nuclear protein extracts were assayed by Western blot,
using a second Mab IgG1anti-PRL (6F11). UT, untreated cells; hrPRL,
human recombinant PRL; β-actina, as internal control.
Additional file 3: Figure S2. Colocalization of PRLr and PRL in THP-1
monocytes activated with LPS. Representative fluorescent
immunocytochemistry (FI) using THP-1 monocytes untreated (UT) or
activated with LPS 1μg/ml (500X) and harvested after: A, 1 h; B, 4 h; and
C, 48 h; to detect PRLr (a), PRL (b), as well as double
immunocytochemistry for both (c). Negative control showing nonspecific
immunolabelling was determined by omitting primary antibodies in each
experiment performed in triplicate.
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